There are currently no FDA-approved drugs that treat any of the three core symptoms of autism— impaired social interactions; impaired communication; and restricted interests, repetitive behaviors and stereotyped mannerisms.
The ConnectMe clinical research program is being led locally by Dr. John Calcagno,
president, medical director and principle investigator, and his team at Cyn3rgyResearch. Problems with socialization and communication can have a devastating impact on families touched by autism spectrum disorders, which makes the ConnectMe clinical research program one of the most insightful research endeavors to date, in addition to being the largest global program, says John Calcagno, MD, president, medical director and principle investigator at Cyn3rgy Research. As one of the largest independent pediatric research facilities in Oregon, we are committed to being a part of this important global study.”
According to the Centers for Disease Control and Prevention, these autism spectrum disorders affect one out of every 88 children in the US. Two of the most common characteristics of these disorders are problems with social interaction and communication.
About The ConnectMe Clinical Research Program
The ConnectMe clinical research protocols were developed by Forest Research Institute, Inc., under the guidance of the United States Food and Drug Administration (FDA). The investigational drug in the ConnectMe clinical research program contains the active ingredient memantine hydrochloride, in dosage strengths unique to pediatric patients. To learn more about the ConnectMe clinical research program in the United States or to see if your child is eligible to participate in one of the 85+ sites across the country, visit www.connectmetrial.com or call 1 (877) 900-8735.
